J
Janet E. Pope
Researcher at University of Western Ontario
Publications - 593
Citations - 30332
Janet E. Pope is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Rheumatoid arthritis & Population. The author has an hindex of 72, co-authored 557 publications receiving 25112 citations. Previous affiliations of Janet E. Pope include McGill University Health Centre & Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
Canadian Recommendations for Clinical Trials of Pharmacologic Interventions in Rheumatoid Arthritis: Inclusion Criteria and Study Design
Jacob Karsh,Edward C. Keystone,Boulos Haraoui,J. Carter Thorne,Janet E. Pope,Vivian P. Bykerk,Walter P. Maksymowych,Michel Zummer,William G. Bensen,Majed M. Kraishi +9 more
TL;DR: There is an urgent need to modify clinical trial inclusion criteria and other study design features to better reflect the current characteristics of people living with RA in the countries where the new drugs will be used.
Journal ArticleDOI
Medication use in systemic lupus erythematosus.
Sasha Bernatsky,Christine A. Peschken,Paul R. Fortin,Christi A. Pineau,Murray B. Urowitz,Dafna D. Gladman,Janet E. Pope,Marie Hudson,Michel Zummer,C. Douglas Smith,Hector Arbillaga,Ann E. Clarke +11 more
TL;DR: This work presents the first portrayal of determinants of clinical practice patterns in SLE, and offers interesting real-world insights.
Journal ArticleDOI
Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
TL;DR: The adjusted mean EScSG-AI was the most consistent predictor of risk across the study outcomes over 3 years in dcSSc: disease progression defined as Δ ⩾ 1 in any major internal organ, significant decline in forced vital capacity and diffusing capacity of carbon monoxide, severity of visceral disease and HAQ Disability Index worsening.
Journal Article
Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons.
TL;DR: Differences between agents in RA with DMARD failures were less than the minimally clinically important difference for HAQ; therefore, the clinical significance of these differences is unclear.
Journal ArticleDOI
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Andreas Kerschbaumer,Alexandre Sepriano,Sytske Anne Bergstra,Josef S Smolen,Désirée van der Heijde,Roberto Caporali,Christopher Edwards,Patrick Verschueren,Savia de Souza,Janet E. Pope,Y. Takeuchi,Kimme L. Hyrich,Kevin L. Winthrop,Daniel Aletaha,Tanja Stamm,Jan W. Schoones,Robert Landewé +16 more
TL;DR: In this article , a systematic literature review (SLR) investigated the efficacy of conventional synthetic (cs), biological (b), biosimilar and targeted synthetic (ts)DMARDs in patients with RA.